Lees C C, Lojacono A, Thompson C, Danti L, Black R S, Tanzi P, White I R, Campbell S
Harris Birthright Research Centre, King's College Hospital, London, United Kingdom.
Obstet Gynecol. 1999 Sep;94(3):403-8. doi: 10.1016/s0029-7844(99)00296-3.
To compare the efficacy of transdermal glyceryl trinitrate and intravenous (IV) ritodrine as tocolytics.
Two hundred forty-five women with preterm labor and intact membranes between 24 and 36 weeks' gestation were randomized to transdermal glyceryl trinitrate or intravenous ritodrine. Treatment was continued until contractions stopped or a maximum of 7 days. Glyceryl trinitrate was administered as a 10- or 20-mg transdermal patch. Intravenous ritodrine was administered according to nationally available guidelines. The primary outcome was prolongation of gestation expressed as a percentage of the time from entry to 37 weeks. Secondary outcomes were proportion of women who delivered the same day, next day, or within 7 and 14 days of entry, and by 32, 34, and 37 weeks. Analysis was by intention to treat.
Twelve women (5%) were lost to follow-up. Glyceryl trinitrate and ritodrine prolonged gestation by 74% of time to 37 weeks (difference glyceryl trinitrate-ritodrine 0%; 95% confidence interval (CI) -10%, +10%). There was no significant difference in the proportion of women receiving glyceryl trinitrate or ritodrine who delivered within the specified days from study entry or weeks of gestation; however, 42 women who received glyceryl trinitrate and 58 women who received ritodrine delivered by 37 weeks (difference -11%; 95% CI -24%, +2%). No serious maternal side effects were reported for ritodrine or glyceryl trinitrate.
We found no overall difference between glyceryl trinitrate and ritodrine in the acute tocolysis of preterm labor but a suggested advantage of glyceryl trinitrate over ritodrine in reducing preterm delivery rate. The maternal side effect profile and treatment discontinuation rates were fewer for glyceryl trinitrate, suggesting it was a safer alternative to ritodrine.
比较硝酸甘油经皮给药与静脉注射利托君作为宫缩抑制剂的疗效。
将245例妊娠24至36周、胎膜完整的早产妇女随机分为硝酸甘油经皮给药组或静脉注射利托君组。治疗持续至宫缩停止或最长7天。硝酸甘油以10毫克或20毫克的经皮贴片给药。静脉注射利托君根据国内可用指南给药。主要结局是以从入组至37周的时间百分比表示的孕周延长。次要结局是在入组当天、次日或入组后7天和14天内以及在32、34和37周分娩的妇女比例。分析采用意向性治疗。
12名妇女(5%)失访。硝酸甘油和利托君使孕周延长至37周时间的74%(硝酸甘油-利托君差异为0%;95%置信区间(CI)-10%,+10%)。在从研究入组或孕周开始的指定天数内接受硝酸甘油或利托君治疗并分娩的妇女比例没有显著差异;然而,42名接受硝酸甘油治疗的妇女和58名接受利托君治疗的妇女在37周前分娩(差异-11%;95%CI-24%,+2%)。未报告利托君或硝酸甘油有严重的母体副作用。
我们发现硝酸甘油和利托君在早产急性宫缩抑制方面没有总体差异,但硝酸甘油在降低早产率方面比利托君有潜在优势。硝酸甘油的母体副作用情况和治疗中断率较低,表明它是利托君的更安全替代药物。